H. Lee Moffitt Cancer Center and Research Institute
With
National Pediatric Cancer Foundation
Age
1–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be \>1 year of age. There is no upper age limit.
Patients, in the opinion of the enrolling investigator, must be healthy enough to tolerate protocol therapy.
Patients must have a new histologic diagnosis of either: widely metastatic Ewing sarcoma or metastatic CIC-rearranged sarcoma.
Patients must have sufficient tissue submitted (flash frozen tissue, FFPE block, or up to 10 unstained FFPE slides) for correlative testing. This may be from a primary or metastatic site.
Patients must not have received any prior systemic therapy with the exception that they may have started an initial cycle of vincristine/doxorubicin/cyclophosphamide (VDC) prior to enrollment, i.e. VDC may have been given, but not ifosfamide/etoposide (IE).
Adequate organ function.
Males and females of reproductive potential may not participate unless they have agreed to the use of, at minimum, two methods of contraception during and after treatment or abstinence.
All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.
Pregnancy or Breast Feeding: Pregnant or breast-feeding women will not be entered on this study, because there is no available information regarding human fetal or teratogenic toxicities. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to starting protocol therapy.
You may not be if
Patients with localized disease or lung only metastases for Ewing sarcoma or localized disease for CIC-rearranged sarcomas.
Patients who are receiving any other investigational agents for their cancer.
Patients with a history of cancer that was treated with myelosuppressive chemotherapy or radiation therapy.
Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer.
Clareo Health | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
